This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study


Taipale, Heidi, Tanskanen, Antti, Koponen, Marjaana, Tolppanen, Anna-Maija, Tiihonen, Jari, Hartikainen, Sirpa


International Clinical Psychopharmacology, Volume: 29, No.: 4, Pages.: 216-223

Year of Publication



The objective of this study was to investigate the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation of AChEI therapy during 2006-2009. We utilized data from a nationwide sample of community-dwelling individuals with a clinically verified Alzheimer’s disease diagnosed during the year 2005 (n=6858) as a part of the MEDALZ-2005 study. During the 4-year follow-up, 84% used AChEI and 47% used memantine. Altogether, 22% of the sample used both drugs concomitantly. The median duration of the first AChEI use period was 860 (interquartile range 295-1458) days and 1103 (interquartile range 489-1487) days for the total duration of AChEI use. Although 20% of the AChEI users discontinued the use during the first year, over half of them restarted later. The risk of discontinuation was higher for rivastigmine [hazard ratio 1.34 (confidence interval 1.22-1.48)] and galantamine users [hazard ratio 1.23 (confidence interval 1.15-1.37)] compared with donepezil users in the adjusted model. In conclusion, median time for AChEI use was over 3 years and every fifth Alzheimer’s disease patient used AChEI and memantine concomitantly during the follow-up. The low rate of discontinuation is consistent with the Finnish Care Guideline but in contrast to the results reported from many other countries.;

Bibtex Citation

@article{Taipale_2014, doi = {10.1097/yic.0000000000000032}, url = {}, year = 2014, month = {jul}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {29}, number = {4}, pages = {216--223}, author = {Heidi Taipale and Antti Tanskanen and Marjaana Koponen and Anna-Maija Tolppanen and Jari Tiihonen and Sirpa Hartikainen}, title = {Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland}, journal = {International Clinical Psychopharmacology} }


acetylcholinesterase, achei, adverse effects, aged, aged, 80 and over, alzheimer disease, and, cholinesterase inhibitors, cohort studies, diagnostic and statistical manual of mental disorders, drug monitoring, drug prescriptions, drug therapy, drug therapy combination, excitatory amino acid antagonists, female, finland, galantamine, guideline adherence, humans, indans, inhibitor, male, medication, memantine, nootropic agents, phenylcarbamates, piperidines, practice guidelines as topic, proportional hazards models, registries, therapeutic use, use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study, Cost and service use study

Type of Outcomes

Service use or cost reductions (incl. hospital use reduction, care home admission delay)



Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime